We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.44 | 0 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
Celgene Corp. (CELG) said Monday results from the phase 3 STYLE study showed Otezla achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician's Global Assessment response after 16 weeks when compared with a placebo.
Otezla is for use by patients with moderate to severe plaque psoriasis.
The company also said statistical significance was met for the secondary endpoint of the whole body itch numeric rating scale at week 16.
Terrie Curran, president of Celgene's inflammation and immunology operations, said the company was "encouraged by the significant improvements in this trial and look forward to sharing these data to further enhance the Otezla label."
Celgene said the safety profile was generally consistent with the known safety profile of Otezla, and no new safety signals were identified in the trial.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 08, 2018 17:29 ET (21:29 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
